Also trades as: 0QZU.L (LSE) · $vol 1M · VX1.DE (XETRA) · $vol 0M

$521.03

+3.54 (+0.68%)

Weekly Expected Move ±4.1%

$480 $502 $524 $546 $567

NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 62 · $132.1B mcap · 253M float · 0.544% daily turnover · Short 52% of daily vol

Credit Risk of going bust: lower than 94% of companies Debt: 1.5% of company value Bonds: none of note held by US funds details ▾

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NARROW EDGE

56.4 / 100

NoneWeakNarrowWide

Primary source: Network Effects · ROIC: 28.3% · 5Y Avg: 31.9%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. VRTX has a Narrow competitive edge (56.4/100) — meaningful but not impregnable advantages over competitors. The primary source of advantage is Network Effects. ROIC of 28.3% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

$442

Low

$591

Avg Target

$665

High

Based on 13 analysts since Aug 3, 2026 earnings

Analyst Recommendations

Strong Buy: 0Buy: 47Hold: 8Sell: 1Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$590.69

Analysts13

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-10-08	RBC Capital	—	$570	$576	+6	+14.6%	$502.62
2026-09-28	UBS	—	$585	$615	+30	+16.5%	$528.04
2026-09-23	Jefferies	Akash Tewari	$580	$640	+60	+24.3%	$514.99
2026-09-22	H.C. Wainwright	Andrew Fein	$591	$641	+50	+23.3%	$519.67
2026-09-01	Morgan Stanley	Terence Flynn	$616	$665	+49	+21.4%	$547.65
2026-09-01	Goldman Sachs	—	$598	$653	+55	+19.9%	$544.52
2026-08-11	Bernstein	Jeffrey Walch	$572	$608	+36	+14.7%	$530.29
2026-08-10	Wolfe Research	Andy Chen	$576	$562	-14	+7.5%	$522.78
2026-08-05	Truist Financial	—	$560	$565	+5	+15.6%	$488.56
2026-08-05	Barclays	—	$615	$617	+2	+28.9%	$478.70
2026-08-04	Cantor Fitzgerald	—	$590	$595	+5	+26.4%	$470.72
2026-08-04	Canaccord Genuity	—	$436	$442	+6	-6.1%	$470.72
2026-08-04	Stifel Nicolaus	—	$466	$500	+34	+6.2%	$470.72
2026-07-13	UBS	—	$545	$585	+40	+21.4%	$481.70
2026-07-13	Truist Financial	—	$542	$560	+18	+16.9%	$479.01
2026-07-07	RBC Capital	—	$543	$570	+27	+7.6%	$529.59
2026-07-07	Robert W. Baird	—	$240	$350	+110	-33.9%	$529.59
2026-05-27	Truist Financial	Danielle Brill	$525	$542	+17	+24.3%	$435.93
2026-05-06	Barclays	—	$607	$615	+8	+44.9%	$424.36
2026-05-05	Morgan Stanley	—	$612	$616	+4	+47.5%	$417.72
2026-05-05	RBC Capital	Brian Abrahams	$541	$543	+2	+26.3%	$429.85
2026-05-05	Bernstein	—	$577	$572	-5	+33.1%	$429.85
2026-05-05	Canaccord Genuity	—	$437	$436	-1	+1.4%	$429.85
2026-04-30	Canaccord Genuity	—	$441	$437	-4	+3.3%	$423.24
2026-04-10	Morgan Stanley	—	$570	$612	+42	+40.1%	$436.89
2026-03-10	Truist Financial	Joon Lee	$490	$525	+35	+5.2%	$499.14
2026-03-10	Jefferies	Akash Tewari	$550	$580	+30	+16.8%	$496.50
2026-03-02	BMO Capital	Evan David Seigerman	$530	$600	+70	+23.1%	$487.57
2026-02-17	Canaccord Genuity	—	$361	$441	+80	-10.3%	$491.47
2026-02-17	Barclays	Eliana Merle	$606	$607	+1	+23.5%	$491.47
2026-02-17	H.C. Wainwright	Andrew Fein	$518	$591	+73	+20.3%	$491.47
2026-02-13	Morgan Stanley	Terence Flynn	$564	$570	+6	+14.6%	$497.42
2026-02-13	Scotiabank	Louise Chen	$442	$558	+116	+13.0%	$493.98
2026-02-13	RBC Capital	—	$546	$541	-5	+9.1%	$496.02
2026-02-13	Bernstein	—	Initiated	$577	—	+16.0%	$497.21
2026-02-13	Cantor Fitzgerald	—	$485	$590	+105	+19.2%	$495.11
2026-02-13	Stifel Nicolaus	Paul Matteis	$445	$466	+21	+0.2%	$465.02
2026-02-13	H.C. Wainwright	Andrew Fein	$478	$518	+40	+11.4%	$465.02
2026-01-27	Barclays	—	$414	$606	+192	+27.8%	$474.17
2026-01-26	UBS	—	$535	$545	+10	+15.0%	$474.09
2026-01-23	Evercore ISI	Cory Kasimov	$438	$530	+92	+13.0%	$469.11
2026-01-22	RBC Capital	Brian Abrahams	$415	$546	+131	+18.4%	$461.14
2026-01-06	UBS	Michael Yee	$553	$535	-18	+14.2%	$468.38
2025-12-29	Leerink Partners	—	$456	$525	+69	+13.6%	$462.12
2025-12-05	Morgan Stanley	—	$516	$564	+48	+22.2%	$461.48
2025-12-03	Morgan Stanley	Terence Flynn	$438	$516	+78	+19.1%	$433.15
2025-11-04	RBC Capital	—	$420	$415	-5	-2.8%	$426.93
2025-11-04	Cantor Fitzgerald	Carter Gould	$535	$485	-50	+13.5%	$427.30
2025-11-04	Stifel Nicolaus	—	$455	$445	-10	+4.5%	$426.00
2025-11-04	Barclays	Gena Wang	$285	$414	+129	-2.8%	$426.00

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A-

Oct 27, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. VRTX receives an overall rating of A-. Strongest factors: DCF (4/5), ROE (5/5), ROA (5/5). Areas of concern: P/E (2/5), P/B (1/5).

Rating Change History

Date	From	To
2026-10-12	B+	A-
2026-08-14	A-	B+
2026-08-13	B+	A-
2026-08-05	A-	B+
2026-05-05	B+	A-
2026-04-01	A-	B+
2026-03-23	B+	A-
2026-03-02	A-	B+
2026-02-23	B+	A-
2026-02-13	A-	B+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 76 Grade A+

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. VRTX scores highest in Safety (100/100) and lowest in Value (44/100). An overall grade of A+ places VRTX among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

12.89

Safe Zone

Piotroski F-Score

6/9

✓ ✓ ✓ ✗ ✗ ✓ ✓ ✗ ✓

Beneish M-Score

-2.37

Unlikely Manipulator

Ohlson O-Score

-11.47

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AAA

Score: 97.0/100

Trend: Stable

Earnings Quality

75/100

OCF/NI: 0.97x

Accruals: 0.4%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. VRTX scores 12.89, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. VRTX scores 6/9, indicating moderate financial health — some areas of strength offset by weaknesses in others. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. VRTX's score of -2.37 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. VRTX's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. VRTX receives an estimated rating of AAA (score: 97.0/100), with a stable trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). VRTX's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

30.08x

PEG

1.34x

P/S

10.46x

P/B

6.53x

P/FCF

33.46x

P/OCF

29.59x

EV/EBITDA

22.02x

EV/Revenue

9.60x

EV/EBIT

22.94x

EV/FCF

31.91x

Earnings Yield

3.47%

FCF Yield

2.99%

Shareholder Yield

1.76%

Graham Number

$175.20

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 30.1x earnings, VRTX commands a growth premium. Graham's intrinsic value formula yields $175.20 per share, 197% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.835

NI / EBT

Interest Burden

0.999

EBT / EBIT

EBIT Margin

0.418

EBIT / Rev

Asset Turnover

0.491

Rev / Assets

Equity Multiplier

1.375

Assets / Equity

ROE

23.5%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. VRTX's ROE of 23.5% is driven by Asset Turnover (0.491), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

10.06%

Fair P/E

28.62x

Intrinsic Value

$493.11

Price/Value

1.01x

Margin of Safety

-0.73%

Premium

0.73%

Assessment

Neutral

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with VRTX's realized 10.1% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. VRTX trades at a 1% premium to its adjusted intrinsic value of $493.11, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 28.6x compares to the current market P/E of 30.1x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$521.03

Median 1Y

$576.54

5th Pctile

$339.53

95th Pctile

$976.21

Ann. Volatility

31.8%

Analyst Target

$590.69

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Reshma Kewalramani CEO and President	$1,600,000	$15,002,270	$21,144,261
Stuart A. Arbuckle Former EVP & Chief Operating Officer	$521,486	$9,341,927	$9,996,347
Charles F. Wagner, Jr. EVP & Chief Operating and Financial Officer	$974,808	$5,250,817	$8,241,809
Nia Tatsis EVP & Chief Regulatory and Quality Officer	$750,000	$4,900,522	$6,974,920
Amit Sachdev EVP & Chief Patient and External Affairs Officer	$700,000	$4,900,522	$6,777,243
Carmen Bozic EVP & Chief Medical Officer	$835,000	$4,375,531	$6,646,321

CEO Pay Ratio

77:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $21,144,261

Avg Employee Cost (SGA/emp): $273,922

Employees: 6,400

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

6,400

+4.9% YoY

Revenue / Employee

$1,886,656

Rev: $12,074,600,000

Profit / Employee

$617,688

NI: $3,953,200,000

SGA / Employee

$273,922

Avg labor cost proxy

R&D / Employee

$586,516

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
ROE	24.6%	24.9%	24.6%	30.2%	29.0%	27.7%	25.7%	24.6%	23.5%	23.0%	24.4%	-3.2%	-3.0%	-3.2%	-5.6%	22.8%	22.3%	22.5%	24.2%	23.5%	23.54%
ROA	18.2%	18.6%	18.6%	23.0%	22.3%	21.0%	19.6%	18.7%	18.1%	17.7%	18.7%	-2.4%	-2.2%	-2.4%	-4.2%	16.5%	15.6%	16.2%	17.6%	17.1%	17.12%
ROIC	60.9%	67.4%	70.9%	93.9%	82.6%	83.8%	65.8%	62.0%	58.6%	44.2%	38.9%	8.0%	4.6%	4.2%	-4.9%	26.5%	25.6%	22.8%	28.4%	28.3%	28.31%
ROCE	26.3%	24.7%	24.2%	30.7%	29.0%	27.8%	26.5%	25.6%	24.0%	23.1%	23.9%	1.5%	1.6%	1.5%	-1.5%	22.1%	21.9%	20.9%	22.9%	22.5%	22.49%
Gross Margin	88.1%	88.1%	88.3%	88.1%	87.6%	87.7%	88.8%	87.6%	87.2%	85.4%	87.3%	85.9%	85.8%	85.5%	86.9%	86.3%	86.5%	85.6%	86.8%	85.3%	85.33%
Operating Margin	53.1%	42.3%	49.6%	50.4%	48.3%	44.9%	32.8%	41.2%	41.8%	39.3%	42.4%	-1.3%	40.3%	35.2%	22.7%	38.8%	38.6%	40.3%	38.1%	37.4%	37.41%
Net Margin	42.9%	37.2%	36.3%	36.9%	39.9%	35.6%	29.5%	36.7%	41.7%	38.5%	40.9%	-1.4%	37.7%	31.4%	23.3%	34.8%	35.2%	36.9%	34.5%	33.0%	32.99%
EBITDA Margin	56.9%	44.4%	47.9%	49.0%	52.6%	48.9%	39.7%	48.7%	49.6%	48.3%	50.0%	-1.3%	46.4%	40.7%	28.2%	45.1%	44.1%	43.0%	43.8%	43.5%	43.45%
FCF Margin	26.9%	31.8%	30.8%	45.4%	43.8%	44.0%	42.3%	40.8%	43.6%	33.8%	34.7%	-13.2%	-12.2%	-8.9%	-11.3%	30.6%	28.5%	26.5%	30.3%	30.1%	30.07%
OCF Margin	30.0%	34.9%	33.7%	48.1%	46.5%	46.2%	44.2%	42.8%	45.4%	35.8%	38.7%	-9.1%	-7.9%	-4.5%	-8.8%	33.7%	31.7%	30.2%	34.6%	34.0%	34.01%
ROE 3Y Avg	snapshot only																				13.21%
ROE 5Y Avg	snapshot only																				17.63%
ROA 3Y Avg	snapshot only																				9.59%
ROIC 3Y Avg	snapshot only																				17.03%
ROIC Economic	snapshot only																				18.52%
Cash ROA	snapshot only																				15.65%
Cash ROIC	snapshot only																				29.87%
CROIC	snapshot only																				26.41%
NOPAT Margin	snapshot only																				32.23%
Pretax Margin	snapshot only																				41.78%
R&D / Revenue	snapshot only																				31.38%
SGA / Revenue	snapshot only																				15.91%
SBC / Revenue	snapshot only																				5.46%

Valuation

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
P/E Ratio	21.65	24.10	27.46	22.82	22.95	22.63	25.16	27.23	26.12	29.33	27.15	-246.94	-252.99	-195.86	-127.22	31.69	27.45	29.37	26.38	28.83	30.083
P/S Ratio	6.61	7.45	8.47	8.73	8.64	8.42	8.91	9.64	9.39	10.76	10.72	11.71	11.43	9.52	11.33	10.09	8.61	9.64	9.34	10.06	10.461
P/B Ratio	4.94	5.59	6.17	6.11	5.77	5.40	5.68	5.92	5.49	6.04	5.88	8.19	7.77	6.39	7.63	6.71	5.83	6.22	5.91	6.27	6.533
P/FCF	24.55	23.43	27.46	19.25	19.70	19.15	21.08	23.63	21.55	31.81	30.85	-88.45	-93.84	-107.26	-100.01	32.93	30.23	36.35	30.85	33.46	33.459
P/OCF	22.01	21.35	25.13	18.14	18.57	18.20	20.13	22.53	20.68	30.01	27.67	—	—	—	—	29.97	27.13	31.97	26.99	29.59	29.587
EV/EBITDA	13.99	17.10	19.60	15.61	15.65	14.72	16.56	18.00	17.59	20.79	19.91	249.65	225.16	207.34	-1589.24	24.06	20.69	23.31	20.25	22.02	22.021
EV/Revenue	5.75	6.59	7.54	7.72	7.61	7.31	7.86	8.54	8.23	9.70	9.79	11.24	10.97	9.13	10.92	9.67	8.23	9.42	8.91	9.60	9.596
EV/EBIT	14.59	17.87	20.49	16.15	16.20	15.23	17.15	18.64	18.24	21.64	20.72	452.69	391.16	360.22	-437.76	25.14	21.61	24.35	21.10	22.94	22.936
EV/FCF	21.38	20.71	24.45	17.03	17.36	16.63	18.61	20.93	18.89	28.69	28.18	-84.89	-90.12	-102.80	-96.39	31.55	28.90	35.50	29.43	31.91	31.911
Earnings Yield	4.6%	4.1%	3.6%	4.4%	4.4%	4.4%	4.0%	3.7%	3.8%	3.4%	3.7%	-0.4%	-0.4%	-0.5%	-0.8%	3.2%	3.6%	3.4%	3.8%	3.5%	3.47%
FCF Yield	4.1%	4.3%	3.6%	5.2%	5.1%	5.2%	4.7%	4.2%	4.6%	3.1%	3.2%	-1.1%	-1.1%	-0.9%	-1.0%	3.0%	3.3%	2.8%	3.2%	3.0%	2.99%
PEG Ratio	snapshot only																				1.338
Price/Tangible Book	snapshot only																				6.775
EV/OCF	snapshot only																				28.218
EV/Gross Profit	snapshot only																				11.153
Acquirers Multiple	snapshot only																				24.864
Shareholder Yield	snapshot only																				1.76%
Graham Number	snapshot only																				$175.20

Leverage & Solvency

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Current Ratio	4.62	4.46	4.75	4.50	4.70	4.83	4.28	4.14	4.08	3.99	3.50	2.52	2.47	2.69	2.65	2.52	2.36	2.90	3.02	3.19	3.185
Quick Ratio	4.45	4.30	4.60	4.36	4.55	4.66	4.11	3.96	3.89	3.78	3.29	2.26	2.20	2.35	2.29	2.16	2.00	2.46	2.57	2.74	2.737
Debt/Equity	0.09	0.10	0.08	0.07	0.06	0.06	0.05	0.05	0.05	0.05	0.04	0.06	0.11	0.11	0.10	0.09	0.11	0.21	0.10	0.10	0.098
Net Debt/Equity	-0.64	-0.65	-0.68	-0.70	-0.69	-0.71	-0.67	-0.68	-0.68	-0.59	-0.51	-0.33	-0.31	-0.27	-0.28	-0.28	-0.26	-0.15	-0.27	-0.29	-0.290
Debt/Assets	0.07	0.07	0.06	0.05	0.05	0.05	0.04	0.04	0.03	0.04	0.03	0.05	0.08	0.08	0.07	0.06	0.07	0.15	0.08	0.07	0.072
Debt/EBITDA	0.30	0.33	0.29	0.21	0.20	0.20	0.18	0.17	0.16	0.18	0.14	2.01	3.29	3.61	-21.61	0.33	0.39	0.80	0.37	0.36	0.359
Net Debt/EBITDA	-2.08	-2.25	-2.41	-2.03	-2.12	-2.23	-2.20	-2.32	-2.48	-2.26	-1.89	-10.45	-9.31	-9.00	59.66	-1.06	-0.96	-0.56	-0.98	-1.07	-1.068
Interest Coverage	44.83	45.39	48.16	66.71	70.07	78.23	82.27	90.90	96.54	100.32	111.61	6.14	7.76	9.12	-11.94	258.29	348.55	350.11	502.52	800.23	800.227
Equity Multiplier	1.32	1.33	1.31	1.31	1.28	1.30	1.31	1.32	1.32	1.29	1.29	1.36	1.42	1.37	1.39	1.40	1.44	1.40	1.37	1.35	1.354
Cash Ratio	snapshot only																				1.994
Debt Service Coverage	snapshot only																				833.485
Cash to Debt	snapshot only																				3.971
FCF to Debt	snapshot only																				1.920
Defensive Interval	snapshot only																				608.5 days

Efficiency & Turnover

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Asset Turnover	0.60	0.60	0.60	0.60	0.59	0.57	0.55	0.53	0.50	0.48	0.47	0.51	0.48	0.49	0.47	0.52	0.50	0.49	0.50	0.49	0.491
Inventory Turnover	2.97	2.85	3.00	2.88	2.89	2.66	2.52	2.36	2.19	2.10	1.98	1.85	1.67	1.57	1.43	1.31	1.19	1.14	1.08	1.08	1.080
Receivables Turnover	7.54	7.49	7.00	7.38	7.00	6.93	6.48	6.58	6.60	6.57	6.09	6.43	6.46	6.94	6.17	6.43	6.34	6.57	6.45	6.27	6.269
Payables Turnover	7.30	5.17	6.35	6.09	8.20	4.33	4.43	4.09	4.68	3.77	3.97	4.06	3.82	3.93	3.89	4.12	0.73	3.78	3.60	4.04	4.044
DSO	48	49	52	49	52	53	56	55	55	56	60	57	57	53	59	57	58	56	57	58	58.2 days
DIO	123	128	122	127	126	137	145	154	167	173	184	198	219	232	256	278	307	320	339	338	338.0 days
DPO	50	71	57	60	45	84	82	89	78	97	92	90	95	93	94	89	503	97	101	90	90.3 days
Cash Conversion Cycle	121	106	116	116	134	106	119	121	144	132	152	164	180	192	221	246	-138	278	295	306	305.9 days
Fixed Asset Turnover	snapshot only																				3.793
Operating Cycle	snapshot only																				396.2 days
Cash Velocity	snapshot only																				1.608
Capital Intensity	snapshot only																				2.172

Growth (YoY)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue	19.0%	22.1%	23.9%	24.9%	22.0%	17.9%	15.9%	13.8%	11.0%	10.5%	10.6%	8.7%	10.0%	11.6%	9.0%	10.5%	10.4%	9.3%	10.4%	10.6%	10.56%
Net Income	-19.1%	-13.6%	-11.3%	60.4%	50.4%	41.8%	33.0%	5.3%	6.0%	9.0%	23.3%	-1.1%	-1.1%	-1.1%	-1.2%	8.4%	8.7%	8.4%	5.4%	21.1%	21.10%
EPS	-17.8%	-11.6%	-9.9%	61.8%	50.5%	40.0%	31.8%	4.6%	5.6%	8.7%	22.9%	-1.1%	-1.1%	-1.1%	-1.2%	8.4%	8.8%	8.5%	5.4%	22.6%	22.62%
FCF	-35.6%	-19.5%	-19.6%	1.1%	98.7%	63.0%	58.7%	2.4%	10.3%	-15.0%	-9.1%	-1.4%	-1.3%	-1.3%	-1.4%	3.6%	3.6%	4.3%	3.9%	8.5%	8.47%
EBITDA	-4.4%	-11.2%	-11.4%	59.6%	44.2%	52.0%	43.0%	9.1%	6.8%	3.8%	14.5%	-89.7%	-88.5%	-89.5%	-1.0%	8.9%	8.0%	9.0%	71.7%	19.9%	19.86%
Op. Income	-0.4%	-2.6%	-2.9%	79.9%	56.7%	54.8%	37.8%	-2.8%	-6.6%	-11.0%	3.6%	-1.1%	-1.1%	-1.1%	-1.2%	12.3%	15.8%	19.3%	7.4%	24.2%	24.17%
OCF Growth	snapshot only																				11.61%
Asset Growth	snapshot only																				14.09%
Equity Growth	snapshot only																				17.89%
Debt Growth	snapshot only																				29.47%
Shares Change	snapshot only																				-1.24%

Growth (CAGR)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue 3Y	36.1%	35.5%	34.5%	34.2%	34.0%	29.0%	24.1%	20.7%	17.2%	16.7%	16.6%	15.6%	14.2%	13.3%	11.8%	11.0%	10.5%	10.5%	10.0%	9.9%	9.92%
Revenue 5Y	33.8%	34.8%	31.5%	31.4%	30.5%	29.1%	30.7%	29.4%	27.8%	26.5%	25.5%	24.5%	24.0%	21.5%	18.2%	16.1%	14.4%	14.2%	13.8%	13.6%	13.56%
EPS 3Y	49.8%	4.1%	4.7%	13.1%	15.3%	41.7%	29.7%	17.8%	9.3%	10.4%	13.4%	—	—	—	—	4.4%	4.2%	6.5%	10.6%	10.1%	10.06%
EPS 5Y	—	—	68.4%	64.6%	74.4%	65.6%	70.3%	51.7%	39.8%	11.4%	13.2%	—	—	—	—	12.2%	7.0%	8.4%	9.9%	17.7%	17.69%
Net Income 3Y	49.8%	3.8%	4.4%	13.0%	15.1%	41.3%	29.2%	17.4%	8.8%	10.1%	13.3%	—	—	—	—	4.4%	3.9%	6.0%	10.0%	9.4%	9.40%
Net Income 5Y	—	—	69.7%	65.6%	75.7%	66.0%	70.5%	52.0%	39.9%	11.5%	13.3%	—	—	—	—	11.8%	6.4%	7.8%	9.5%	17.2%	17.21%
EBITDA 3Y	54.7%	60.4%	54.6%	63.1%	67.5%	41.7%	32.1%	23.5%	13.7%	11.9%	13.2%	-43.6%	-43.9%	-45.0%	—	3.6%	3.3%	3.1%	7.2%	6.8%	6.85%
EBITDA 5Y	—	1.1%	53.9%	59.4%	2.0%	1.1%	1.4%	79.8%	41.6%	45.5%	43.4%	-13.3%	-10.5%	-20.8%	—	13.9%	8.7%	8.2%	9.3%	16.3%	16.27%
Gross Profit 3Y	36.6%	36.2%	35.1%	35.0%	34.7%	29.5%	24.5%	20.8%	17.1%	16.3%	16.1%	15.0%	13.4%	12.5%	11.0%	10.1%	9.7%	9.8%	9.3%	9.1%	9.13%
Gross Profit 5Y	34.1%	34.9%	31.0%	31.1%	30.2%	28.8%	30.8%	29.6%	28.1%	26.7%	25.6%	24.5%	23.9%	21.3%	17.8%	15.7%	13.9%	13.7%	13.4%	13.1%	13.08%
Op. Income 3Y	61.2%	63.6%	55.3%	66.7%	75.1%	53.2%	35.1%	23.8%	13.4%	10.3%	11.5%	—	—	—	—	-1.3%	-1.3%	-0.3%	5.7%	7.1%	7.10%
Op. Income 5Y	—	2.3%	58.6%	64.2%	1.6%	1.0%	—	1.1%	43.7%	43.3%	39.9%	—	—	—	—	13.4%	8.4%	8.4%	9.6%	16.5%	16.52%
FCF 3Y	21.9%	27.0%	24.9%	38.9%	40.9%	38.0%	25.2%	14.9%	12.2%	3.7%	5.1%	—	—	—	—	-2.6%	-4.4%	-6.6%	-1.6%	-0.7%	-0.71%
FCF 5Y	96.1%	68.1%	39.7%	44.5%	40.7%	39.4%	40.4%	35.7%	31.7%	23.2%	23.0%	—	—	—	—	6.5%	2.3%	1.3%	4.0%	16.4%	16.39%
OCF 3Y	21.8%	27.7%	25.9%	39.4%	41.2%	38.1%	25.5%	15.6%	10.9%	2.8%	5.5%	—	—	—	—	-1.4%	-2.8%	-4.2%	1.3%	1.8%	1.81%
OCF 5Y	95.3%	62.1%	39.0%	43.6%	39.6%	37.3%	37.4%	33.2%	29.9%	22.7%	24.1%	—	—	—	—	7.9%	3.0%	2.2%	4.8%	15.1%	15.15%
Assets 3Y	39.8%	29.1%	29.6%	30.4%	30.5%	29.7%	28.7%	25.8%	24.3%	24.6%	25.4%	18.1%	20.8%	18.8%	17.1%	15.5%	14.2%	12.9%	11.8%	10.5%	10.46%
Assets 5Y	37.1%	35.9%	37.1%	36.5%	39.2%	38.6%	36.9%	36.2%	36.3%	29.5%	29.6%	23.4%	24.2%	22.1%	20.8%	18.7%	17.1%	17.3%	16.9%	17.5%	17.54%
Equity 3Y	48.6%	31.6%	32.2%	33.0%	35.4%	31.7%	30.7%	27.2%	26.6%	26.5%	27.3%	17.1%	17.9%	17.6%	14.8%	12.9%	10.0%	10.3%	10.3%	9.4%	9.39%
Book Value 3Y	48.6%	32.0%	32.6%	33.2%	35.5%	32.0%	31.3%	27.7%	27.2%	26.8%	27.5%	17.6%	17.7%	17.0%	14.6%	12.9%	10.2%	10.9%	10.9%	10.1%	10.05%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue Stability	0.92	0.95	0.96	0.96	0.96	0.98	1.00	1.00	0.99	0.99	0.99	0.98	0.98	0.98	0.98	0.99	0.99	0.99	0.99	0.99	0.993
Earnings Stability	0.85	0.74	0.76	0.82	0.85	0.73	0.74	0.79	0.80	0.69	0.76	0.11	0.13	0.03	0.06	0.00	0.01	0.00	0.00	0.09	0.086
Margin Stability	0.99	0.99	0.99	0.99	0.99	0.99	1.00	1.00	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.989
Rev. Growth Consistency	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Earn. Growth Consistency	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.000
FCF Positive Streak	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	1	0
Earnings Persistence	0.92	0.95	0.95	0.50	0.50	0.83	0.87	0.98	0.98	0.96	0.91	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.20	0.50	0.500
Earnings Smoothness	0.79	0.85	0.88	0.54	0.60	0.65	0.72	0.95	0.94	0.91	0.79	—	—	—	—	—	—	—	—	0.81	0.809
ROE Trend	-0.14	-0.02	-0.05	0.02	-0.03	-0.03	-0.04	-0.02	-0.03	-0.03	-0.01	-0.28	-0.26	-0.25	-0.28	0.12	0.12	0.13	0.15	0.13	0.128
Gross Margin Trend	0.01	0.01	0.00	0.00	0.00	-0.00	0.00	-0.00	-0.00	-0.01	-0.01	-0.02	-0.02	-0.01	-0.01	-0.01	-0.01	-0.00	-0.00	-0.00	-0.002
FCF Margin Trend	-0.17	-0.10	-0.13	0.08	0.06	0.04	0.03	0.05	0.08	-0.04	-0.02	-0.56	-0.56	-0.48	-0.50	0.17	0.13	0.14	0.19	0.21	0.214
Sustainable Growth Rate	24.6%	24.9%	24.6%	30.2%	29.0%	27.7%	25.7%	24.6%	23.5%	23.0%	24.4%	—	—	—	—	22.8%	22.3%	22.5%	24.2%	23.5%	23.54%
Internal Growth Rate	22.2%	22.8%	22.8%	29.8%	28.7%	26.6%	24.4%	23.0%	22.0%	21.5%	23.1%	—	—	—	—	19.7%	18.5%	19.4%	21.3%	20.7%	20.66%

Cash Flow Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
OCF/Net Income	0.98	1.13	1.09	1.26	1.24	1.24	1.25	1.21	1.26	0.98	0.98	1.93	1.76	0.92	0.99	1.06	1.01	0.92	0.98	0.97	0.975
FCF/OCF	0.90	0.91	0.92	0.94	0.94	0.95	0.96	0.95	0.96	0.94	0.90	1.45	1.54	1.99	1.28	0.91	0.90	0.88	0.87	0.88	0.884
FCF/Net Income	snapshot only																				0.862
OCF/EBITDA	snapshot only																				0.780
CapEx/Revenue	3.1%	3.1%	2.9%	2.8%	2.7%	2.3%	2.0%	2.0%	1.8%	2.0%	4.0%	4.1%	4.2%	4.4%	2.5%	3.0%	3.2%	3.6%	4.3%	3.9%	3.94%
CapEx/Depreciation	snapshot only																				2.263
Accruals Ratio	0.00	-0.02	-0.02	-0.06	-0.05	-0.05	-0.05	-0.04	-0.05	0.00	0.00	0.02	0.02	-0.00	-0.00	-0.01	-0.00	0.01	0.00	0.00	0.004
Sloan Accruals	snapshot only																				0.081
Cash Flow Adequacy	snapshot only																				8.641
Earnings Quality Score	snapshot only																				0.750

Dividends & Buybacks

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
FCF Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	56.1%	62.3%	47.0%	36.1%	16.5%	5.2%	10.9%	11.3%	14.5%	18.1%	17.9%	—	—	—	—	52.5%	70.5%	58.1%	49.9%	50.9%	50.88%
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	2.6%	2.6%	1.7%	1.6%	0.7%	0.2%	0.4%	0.4%	0.6%	0.6%	0.7%	0.9%	1.1%	1.5%	1.5%	1.7%	2.6%	2.0%	1.9%	1.8%	1.76%
Net Buyback Yield	2.5%	2.6%	1.7%	1.6%	0.7%	0.2%	0.4%	0.4%	0.6%	0.6%	0.7%	0.9%	1.1%	1.5%	1.5%	1.7%	2.6%	1.9%	1.8%	1.7%	1.66%
Total Shareholder Return	2.5%	2.6%	1.7%	1.6%	0.7%	0.2%	0.4%	0.4%	0.6%	0.6%	0.7%	0.9%	1.1%	1.5%	1.5%	1.7%	2.6%	1.9%	1.8%	1.7%	1.66%

DuPont Factors

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Tax Burden (NI/EBT)	0.79	0.86	0.86	0.81	0.81	0.78	0.78	0.78	0.81	0.83	0.84	-2.28	-1.85	-2.16	3.29	0.83	0.83	0.85	0.84	0.84	0.835
Interest Burden (EBT/EBIT)	0.98	0.98	0.98	0.98	0.99	0.99	0.99	0.99	0.99	0.99	0.99	0.84	0.87	0.89	1.08	1.00	1.00	1.00	1.00	1.00	0.999
EBIT Margin	0.39	0.37	0.37	0.48	0.47	0.48	0.46	0.46	0.45	0.45	0.47	0.02	0.03	0.03	-0.02	0.38	0.38	0.39	0.42	0.42	0.418
Asset Turnover	0.60	0.60	0.60	0.60	0.59	0.57	0.55	0.53	0.50	0.48	0.47	0.51	0.48	0.49	0.47	0.52	0.50	0.49	0.50	0.49	0.491
Equity Multiplier	1.35	1.34	1.33	1.32	1.30	1.32	1.31	1.31	1.30	1.30	1.30	1.34	1.37	1.33	1.34	1.38	1.43	1.39	1.38	1.38	1.375

Per Share

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
EPS (Diluted TTM)	$8.38	$9.11	$9.50	$12.35	$12.61	$12.76	$12.52	$12.92	$13.31	$13.87	$15.39	$-1.90	$-1.84	$-2.06	$-3.81	$14.05	$14.27	$15.44	$16.93	$17.23	$17.23
Book Value/Share	$36.70	$39.30	$42.29	$46.13	$50.21	$53.45	$55.44	$59.41	$63.36	$67.38	$71.03	$57.24	$59.89	$62.99	$63.57	$66.34	$67.23	$72.88	$75.54	$79.19	$79.75
Tangible Book/Share	$31.30	$33.84	$36.85	$40.76	$43.74	$46.95	$48.95	$52.91	$56.87	$59.99	$63.67	$49.78	$52.53	$55.65	$57.68	$60.46	$61.34	$66.98	$69.67	$73.32	$73.32
Revenue/Share	$27.45	$29.47	$30.82	$32.28	$33.53	$34.31	$35.37	$36.50	$37.05	$37.83	$39.00	$40.04	$40.70	$42.29	$42.77	$44.11	$45.51	$47.01	$47.82	$49.37	$49.72
FCF/Share	$7.39	$9.37	$9.50	$14.64	$14.70	$15.08	$14.95	$14.90	$16.14	$12.79	$13.55	$-5.30	$-4.96	$-3.75	$-4.85	$13.52	$12.95	$12.47	$14.48	$14.85	$14.95
OCF/Share	$8.24	$10.29	$10.39	$15.53	$15.59	$15.87	$15.65	$15.62	$16.81	$13.56	$15.11	$-3.66	$-3.23	$-1.89	$-3.78	$14.86	$14.43	$14.18	$16.55	$16.79	$16.91
Cash/Share	$26.80	$29.28	$31.94	$35.77	$37.65	$41.41	$40.01	$43.15	$45.77	$43.00	$38.96	$22.45	$25.00	$23.48	$23.90	$24.65	$24.41	$25.81	$28.27	$30.71	$30.93
EBITDA/Share	$11.29	$11.35	$11.86	$15.97	$16.29	$17.04	$16.79	$17.32	$17.32	$17.65	$19.17	$1.80	$1.98	$1.86	$-0.29	$17.73	$18.09	$18.99	$21.03	$21.51	$21.51
Debt/Share	$3.38	$3.76	$3.38	$3.28	$3.18	$3.46	$3.03	$2.95	$2.86	$3.10	$2.76	$3.62	$6.52	$6.72	$6.35	$5.90	$7.12	$15.16	$7.75	$7.73	$7.73
Net Debt/Share	$-23.43	$-25.52	$-28.56	$-32.49	$-34.47	$-37.95	$-36.98	$-40.20	$-42.91	$-39.90	$-36.19	$-18.84	$-18.47	$-16.76	$-17.54	$-18.75	$-17.28	$-10.65	$-20.52	$-22.98	$-22.98

Academic Models

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	12.894
Altman Z-Prime	snapshot only																				23.805
Piotroski F-Score	6	8	7	8	8	7	6	4	4	3	4	2	1	4	3	6	8	7	6	6	6
Beneish M-Score	-2.18	-2.32	-2.25	-2.34	-2.43	-2.34	-2.27	-2.25	-2.32	-2.09	-2.05	-2.01	-2.02	-2.25	-2.44	-2.36	-2.36	-2.18	-2.31	-2.37	-2.370
Ohlson O-Score	snapshot only																				-11.475
ROIC (Greenblatt)	snapshot only																				44.26%
Net-Net WC	snapshot only																				$20.99
EVA	snapshot only																				$2631787651.14

Credit

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Credit Rating	snapshot only																				AAA
Credit Score	96.99	96.92	96.91	97.18	97.16	97.51	96.95	97.19	97.00	96.92	96.78	81.31	81.33	81.75	65.13	96.99	96.67	96.90	96.86	96.98	96.982
Credit Grade	snapshot only																				1
Credit Trend	snapshot only																				-0.010
Implied Spread (bps)	snapshot only																				50.000
Industry Credit Rank	snapshot only																				96
Sector Credit Rank	snapshot only																				92

VRTX NASDAQ

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet